Read by QxMD icon Read

Multiple Sclerosis and related Disorders

Chris Hawkes, Fred Lublin, Gavin Giovannoni
No abstract text is available yet for this article.
September 2016: Multiple Sclerosis and related Disorders
Douglas D Gunzler, Nathan Morris, Adam Perzynski, Daniel Ontaneda, Farren Briggs, Deborah Miller, Robert A Bermel
BACKGROUND: Trajectories of depression over time may be heterogeneous in Multiple Sclerosis (MS) patients. Describing these trajectories will help clinicians understand better the progression of depression in MS patients to aid in patient care decisions. METHODS: Latent class growth analysis (LCGA) was applied to 3507 MS patients using an electronic health records (EHR) data base to identify subgroups of MS patients based on self-reported depression screening (PHQ-9)...
September 2016: Multiple Sclerosis and related Disorders
Elena Grebenciucova, Anthony T Reder, Jacqueline T Bernard
BACKGROUND: Fingolimod is a disease-modifying agent used in the treatment of relapsing/remitting multiple sclerosis. In MS clinical studies, the overall rate of infections in fingolimod group was overall similar to placebo, except for slightly more common lower respiratory tract infections and to a lesser extent HSV. Recently, an increasing number of cryptococcal infections associated with a long-term use of this medication have been reported. METHODS: We reviewed literature for cases of cryptococcal infection associated with the use of fingolimod and reported a case at our institution, as well as carefully evaluated the established immune mechanisms of the medication and discussed new insights into its short-term and long-term immunologic effects that may become important in the context of risk of infection...
September 2016: Multiple Sclerosis and related Disorders
Asako Tagawa, Tomoko Ogawa, Syuichi Tetsuka, Mieko Otsuka, Ritsuo Hashimoto, Hiroyuki Kato, Katsuyoshi Ando, Hiroki Tanabe
We here report a case involving a 38-year-old female with relapsing and remitting multiple sclerosis who developed reactivation of hepatitis C virus (HCV) during administration of fingolimod for 16 months. She had been previously treated for chronic hepatitis C with pegylated interferon and ribavirin, and kept an undetectable HCV-RNA state for more than 4 years before fingolimod starting. Although the increased risk for viral reactivation, for example of herpes zoster virus and varicella-zoster virus, during fingolimod treatment is known, this is, to our knowledge, the first case report of HCV reappearance...
September 2016: Multiple Sclerosis and related Disorders
Rainer Ehling, Gabriel Bsteh, Franziska Di Pauli, Harald Hegen, Michael Auer, Karin Obermair, Michaela Wagner, Florian Deisenhammer, Markus Reindl, Thomas Berger
BACKGROUND: Paroxysmal (PS) and unusual symptoms (US) as initial manifestation of multiple sclerosis (MS) are rare and often thought to indicate "benign" MS. OBJECTIVE: To investigate prevalence and clinical disease course of patients experiencing PS or US as first clinical manifestation. METHODS: Clinical, MRI and cerebrospinal fluid data of patients presenting with PS and US were obtained retrospectively and compared to patients with classical bout onset (CS)...
September 2016: Multiple Sclerosis and related Disorders
Aleksi Tarkkonen, Eero Rissanen, Terhi Tuokkola, Laura Airas
We present a case where a 30-year-old man with a history of combined MS and Charcot-Marie-Tooth (CMT I) disease was additionally diagnosed and treated for grade II glioma (astrocytoma). Tumefactive MS and gliomas are sometimes difficult to distinguish from one another based on conventional magnetic resonance imaging (MRI). In our case, positron emission tomography (PET) scans with(11)C-methionine ((11)C-MET) and (11)C-PK11195 radioligands were performed to aid in differential diagnostics. The diagnosis was confirmed finally by brain biopsy...
September 2016: Multiple Sclerosis and related Disorders
Georgios Koutsis, Panagiotis Kokotis, Aikaterini E Papagianni, Maria-Eleftheria Evangelopoulos, Constantinos Kilidireas, Nikolaos Karandreas
OBJECTIVE: To integrate neurophysiological findings with clinical and imaging data in a consecutive series of multiple sclerosis (MS) patients developing facial numbness during the course of an MS attack. METHODS: Nine consecutive patients with MS and recent-onset facial numbness were studied clinically, imaged with routine MRI, and assessed neurophysiologically with trigeminal somatosensory evoked potential (TSEP), blink reflex (BR), masseter reflex (MR), facial nerve conduction, facial muscle and masseter EMG studies...
September 2016: Multiple Sclerosis and related Disorders
Dimitrios Rikos, Efthimios Dardiotis, Georgios Tsivgoulis, Elias Zintzaras, Georgios M Hadjigeorgiou
BACKGROUND: Randomized controlled trials (RCTs) are the best tool to evaluate the effectiveness of clinical interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement is an evidence-based approach to improve the quality of RCTs reporting. OBJECTIVE: To evaluate the reporting quality of published RCTs concerning multiple sclerosis from 2000 to 2015 according to a checklist based on the CONSORT statement. METHODS: Electronic databases were searched for English-language RCTs involving patients with multiple sclerosis (MS)...
September 2016: Multiple Sclerosis and related Disorders
Devon S Conway, Nicolas R Thompson, Jeffrey A Cohen
BACKGROUND: The appropriate treatment target in multiple sclerosis (MS) is unclear. Lack of magnetic resonance imaging (MRI) lesion activity, a component of the no evidence of disease activity concept, has been proposed as a treatment target in MS. We used our MS database to investigate whether aggressively pursuing MRI stability by changing disease modifying therapy (DMT) when MRI activity is observed leads to better clinical and imaging outcomes. METHODS: The Knowledge Program (KP) is a database linked to our electronic medical record allowing capture of patient and clinician reported outcomes...
September 2016: Multiple Sclerosis and related Disorders
Pérola de Oliveira, Daniel Rocha de Carvalho, Ivar Viana Brandi, Riccardo Pratesi
PURPOSE: Comorbidity of celiac disease with demyelinating diseases of the central nervous system has been reported since the 1960s. The objective of this study was to determine the serological prevalence of celiac disease in the largest series of patients diagnosed with multiple sclerosis, neuromyelitis optica, or myelitis. METHODS: A prevalence study was conducted with patients evaluated at Sarah Network of Rehabilitation Hospitals between March 2012 and September 2013...
September 2016: Multiple Sclerosis and related Disorders
Bassem I Yamout, Nuhad Abou Zeid, Ali J Taha, Maya M Zeineddine, Samia J Khoury
Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.
September 2016: Multiple Sclerosis and related Disorders
Harold Koendgen, Pei-Ran Ho, Ih Chang
No abstract text is available yet for this article.
September 2016: Multiple Sclerosis and related Disorders
Giovanni Castelnovo, Adelaide Ferraro, Xavier Ayrignac, Dimitri Renard, Clarisse Carra-Dalliere, Pierre Labauge, Eric Thouvenot, Et Luc Jeanjean
No abstract text is available yet for this article.
September 2016: Multiple Sclerosis and related Disorders
Marie Colombe Agahozo, Laura Peferoen, David Baker, Sandra Amor
MS is widely considered to be a T cell-mediated disease although T cell immunotherapy has consistently failed, demonstrating distinct differences with experimental autoimmune encephalomyelitis (EAE), an animal model of MS in which T cell therapies are effective. Accumulating evidence has highlighted that B cells also play key role in MS pathogenesis. The high frequency of oligoclonal antibodies in the CSF, the localization of immunoglobulin in brain lesions and pathogenicity of antibodies originally pointed to the pathogenic role of B cells as autoantibody producing plasma cells...
September 2016: Multiple Sclerosis and related Disorders
S Gustavsen, H B Søndergaard, D B Oturai, B Laursen, J H Laursen, M Magyari, H Ullum, M H Larsen, F Sellebjerg, A B Oturai
BACKGROUND: Epidemiological studies suggest an important role for environmental factors in developing multiple sclerosis (MS). Furthermore several studies have indicated that the effect of environmental factors may be especially pronounced in adolescents. Recently only one study investigated and found that shift work at young age is associated with an increased risk of developing MS. In this study we focused on the effect of shift work in the vulnerable period between 15-19 years. OBJECTIVE: The aim of this study was to investigate the association between shift work at young age and the risk of developing MS...
September 2016: Multiple Sclerosis and related Disorders
R Patejdl, M Wittstock, U K Zettl, K Jost, A Grossmann, J Prudlo
INTRODUCTION: Recently defined consensus criteria for the diagnosis of neuromyelitis optica spectrum disorders (NMOSD) allow establishing the diagnosis in patients without elevated AQP4-Ab and optic nerve involvement. According to the new extended definition, NMOSD is closely associated with extensive spinal cord inflammation occurring in the course of systemic autoimmune diseases as sarcoidosis or lupus erythematodes. NMOSD occurring in the course of hematological disease have not yet been reported in the literature...
September 2016: Multiple Sclerosis and related Disorders
Francois Curtin, Herve Porchet, Robert Glanzman, Hans Martin Schneble, Virginie Vidal, Marie-Laure Audoli-Inthavong, Estelle Lambert, Hans Peter Hartung
BACKGROUND: GNbAC1, a humanized monoclonal antibody, is an innovative treatment currently in development for multiple sclerosis (MS) which, contrary to the immunomodulation/immunosuppressive mechanism of action of most of the MS drugs, targets specifically a protein of endogenous retroviral origin supposed to be critical in MS pathogenesis. METHODS: This trial is a randomized placebo controlled 4-arm study with the objective of demonstrating the efficacy of repeated doses of GNbAC1 on the cumulative number of T1 Gd-enhancing lesions measured from Week 12 to 24 in patients with relapsing remitting MS (RRMS)...
September 2016: Multiple Sclerosis and related Disorders
E Cristiano, L Patrucco, J Miguez, D Giunta, J Correale, M Fiol, M C Ysrraelit, F Cáceres, N Fernandez Liguori, M L Saladino, O Garcea, B Silva, R Alonso, A Carrá, M C Curbelo, A Martinez, J Steinberg, S Giachello, M O Melcom, J I Rojas
UNLABELLED: In 1996, the prevalence of multiple sclerosis (MS) for the metropolitan area of Buenos Aires using the capture-recapture method was estimated to be between 14 and 19.8 cases per 100,000 inhabitants. The aim of this study was to update the prevalence to 2014 following the same methodology. METHODS: Gran Buenos Aires is the denomination that refers to the megalopolis comprised by the autonomous city of Buenos Aires and the surrounding conurbation of the province of Buenos Aires...
September 2016: Multiple Sclerosis and related Disorders
Vijayshree Yadav, Gail Marracci, Edward Kim, Rebecca Spain, Michelle Cameron, Shannon Overs, Andrew Riddehough, David K B Li, John McDougall, Jesus Lovera, Charles Murchison, Dennis Bourdette
BACKGROUND: The role that dietary interventions can play in multiple sclerosis (MS) management is of huge interest amongst patients and researchers but data evaluating this is limited. Possible effects of a very-low-fat, plant-based dietary intervention on MS related progression and disease activity as measured by brain imaging and MS related symptoms have not been evaluated in a randomized-controlled trial. Despite use of disease modifying therapies (DMT), poor quality of life (QOL) in MS patients can be a significant problem with fatigue being one of the common disabling symptoms...
September 2016: Multiple Sclerosis and related Disorders
Nicoline Schiess, Katherine Huether, Taghreed Fatafta, Kathryn C Fitzgerald, Peter A Calabresi, Iain Blair, Taoufik Alsaadi, Miklos Szolics
BACKGROUND: Multiple Sclerosis (MS) is an autoimmune disorder leading to central nervous system inflammation. Traditionally, reported MS prevalence rates in the Middle East are low. Few studies include age/sex standardization giving an unreliable estimate of regional prevalence. OBJECTIVE: to determine the prevalence, incidence and characteristics of MS in Abu Dhabi, United Arab Emirates. METHODS: A retrospective chart review was conducted at the four largest hospitals in Abu Dhabi Emirate between 2010 and 2014...
September 2016: Multiple Sclerosis and related Disorders
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"